- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05483543
Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy
July 29, 2022 updated by: Zhengfei Zhu, Fudan University
A Prospective, Phase II, Single-arm Study Evaluating the Efficacy and Safety of Pamiparib in Consolidation Therapy for Limited-stage Small Cell Lung Cancer That Has Not Progressed After Concurrent Chemoradiotherapy
This study is a prospective, single-arm, phase II clinical trial, with 1-year PFS as the endpoint, to evaluate the efficacy and associated toxicity of Pamiparib as single-agent consolidation treatment in patients with limited-stage small cell lung cancer(LS-SCLC) patients who have not progressed following platinum-based concurrent chemoradiotherapy(cCRT) .
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
44
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Xi Yang, MD
- Phone Number: 18918768091
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200032
- Recruiting
- Fudan University Shanghai Cancer Center
-
Contact:
- Zhengfei Zhu, MD
- Phone Number: +86 18017312901
- Email: fuscczzf@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The patient or a legally authorized representative must provide study-specific informed consent prior to study entry, had good compliance and cooperated with the follow-up.
- Age at least 18 years
- Pathologically (histologically or cytologically) proven diagnosis of limited stage small cell lung cancer (Stage Tx, T1-T4, N0-3, M0, American Joint Committee on Cancer [AJCC] staging, 8th edition [Ed.]), within 60 days prior to registration
- Patients must have had measurable disease (per Response Evaluation Criteria in Solid Tumors [RECIST], version 1.1) prior to the required cycle of cCRT
- Patients must be free of disease progression and not be able to receive other antitumor therapy within 6 weeks of completion of cCRT
- Patients must submit archived or freshly biopsied tumor tissue (formalin-fixed, paraffin-embedded tissue block or approximately 15 unstained sections [must have >8 sections]) along with the relevant pathology report.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 within 30 days prior to registration
- Patient life expectancy must be >12 weeks
Exclusion Criteria:
- Mixed SCLC or NSCLC confirmed by histology
- Previous tumor resection for LS-SCLC
- Any patient treatable by surgery or stereotactic body radiation therapy/stereotactic ablative radiation therapy should be excluded
- Expected to receive any other form of anti-tumor therapy during the study period
- Previous treatment with PARP inhibitor drugs
- Any active malignancy within 2 years prior to enrollment, excluding the specific cancers being studied in this study and locally recurrent cancers that have been cured (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, cervical cancer carcinoma in situ or carcinoma in situ of the breast)
- Women who are pregnant, breastfeeding, or planning to become pregnant during the study
- Concurrent participation in another therapeutic clinical trial
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Pamiparib monoagent
Drug: Pamiparib 40mg bid orally
|
Patients will receive Pamiparib 40 mg bid every 3 weeks after cCRT up to 1 year or disease progression according to RECIST v1.1 occur.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
1-year Progression Free Survival Rate
Time Frame: One year after the start of intervention
|
One-year PFS rate was define as the percentage of patients who did not experience disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death due to any cause within 1 year from the date cCRT treatment ended.
|
One year after the start of intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression Free Survival
Time Frame: Two years
|
Progression-free survival according to RECIST v1.1 from date of cCRT treatment ended until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.
For patients whose disease did not progress, PFS was evaluated by censoring patients at their most recent imaging.
|
Two years
|
Overall Survival
Time Frame: Two years
|
Overall survival from date of cCRT treatment ended until the date of end of treatment visit or date of death from any cause, whichever came first, assessed up to 24 months.
Participants still alive at the time of data analysis will be censored at the date of last follow-up.
|
Two years
|
AEs/SAEs
Time Frame: Baseline up to 30 days after the last dose of study drug or before initiation of a new antitumor treatment, whichever occurred first
|
The level of AEs defined by NCI-CTCAE v5.0.
Safety assessments will be assessed and documented after initiation of study drug, regardless of relationship to study drug.
|
Baseline up to 30 days after the last dose of study drug or before initiation of a new antitumor treatment, whichever occurred first
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
June 20, 2022
Primary Completion (ANTICIPATED)
December 31, 2024
Study Completion (ANTICIPATED)
December 31, 2024
Study Registration Dates
First Submitted
July 29, 2022
First Submitted That Met QC Criteria
July 29, 2022
First Posted (ACTUAL)
August 2, 2022
Study Record Updates
Last Update Posted (ACTUAL)
August 2, 2022
Last Update Submitted That Met QC Criteria
July 29, 2022
Last Verified
July 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LSSCLCPARPI-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Limited Stage Small Cell Lung Cancer
-
Shanghai Chest HospitalRecruitingSmall Cell Lung Carcinoma | Small-cell Lung Cancer | Small Cell Lung Cancer Limited Stage | Small Cell Lung Cancer Extensive Stage | Small Cell Lung Cancer, Combined TypeChina
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
European Organisation for Research and Treatment...UNICANCERRecruitingExtensive-stage Small-cell Lung Cancer | Limited Stage Small Cell Lung CancerUnited Kingdom, Belgium, Switzerland, Italy, France, Germany, Poland, Spain, Austria
-
Intergroupe Francophone de Cancerologie ThoraciqueCompletedSmall Cell Lung Cancer | Small Cell Lung Cancer Limited Stage | Small Cell Lung Cancer Extensive StageFrance
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedTobacco Use Disorder | Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Limited Stage Small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB...United States
-
Vanderbilt-Ingram Cancer CenterMerck Sharp & Dohme LLCRecruitingLimited Stage Lung Small Cell Carcinoma | Stage III Lung Cancer | Stage I Lung Cancer | Stage II Lung CancerUnited States
-
National Cancer Institute (NCI)NRG OncologyActive, not recruitingStage III Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Limited Stage Lung Small Cell Carcinoma | Stage I Lung Cancer AJCC v8United States, Japan
-
National Cancer Institute (NCI)TerminatedExtensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Limited Stage Small Cell Lung CancerUnited States
-
National Cancer Institute (NCI)CompletedExtensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Limited Stage Small Cell Lung CancerUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...CompletedSCLC | Small-cell Lung Cancer | Small Cell Lung Cancer Limited StageUnited States
Clinical Trials on Pamiparib
-
Peter MacCallum Cancer Centre, AustraliaRecruiting
-
BeiGeneCompletedAdvanced Solid TumorsUnited Kingdom
-
BeiGeneTerminatedMetastatic Castration-Resistant Prostate Cancer (mCRPC) | Homologous Recombination Deficiency (HRD)United States, Australia, Puerto Rico, Spain
-
Australia New Zealand Gynaecological Oncology GroupBeiGeneWithdrawn
-
BeiGeneCompletedHER2-negative Breast CancerChina
-
Sun Yat-sen UniversityRecruitingMetastatic Castration-resistant Prostate CancerChina
-
BeiGene USA, Inc.CompletedBrain and Central Nervous System TumorsUnited States, Netherlands, Switzerland
-
BeiGeneActive, not recruiting
-
BeiGeneMyriad Genetic Laboratories, Inc.CompletedSolid TumorsUnited States, Spain, United Kingdom, France, Australia, New Zealand
-
University Hospital, CaenCompleted